Parinda Mehta

Summary

Affiliation: Cincinnati Children's Hospital Medical Center
Country: USA

Publications

  1. ncbi request reprint Pharmacogenetics of acute lymphoblastic leukemia
    Parinda A Mehta
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Curr Opin Hematol 11:434-8. 2004
  2. doi request reprint Numerical chromosomal changes and risk of development of myelodysplastic syndrome--acute myeloid leukemia in patients with Fanconi anemia
    Parinda A Mehta
    Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Cancer Genet Cytogenet 203:180-6. 2010
  3. doi request reprint Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study
    Parinda A Mehta
    Division of Bone Marrow Transplantation Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Biol Blood Marrow Transplant 16:1458-62. 2010
  4. pmc FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report
    Parinda A Mehta
    Division of Hematology Oncology, Cincinnati Children s Hospital and Medical Center, Cincinnati, Ohio 45229, USA
    Clin Cancer Res 14:7896-9. 2008
  5. ncbi request reprint Allogeneic transplantation for childhood ALL
    P A Mehta
    Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Bone Marrow Transplant 41:133-9. 2008
  6. pmc Interleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia
    Parinda A Mehta
    Division of Haematology Oncology, Cincinnati Children s Hospital and Medical Center, Cincinnati, OH 45229, USA
    Br J Haematol 137:152-7. 2007
  7. ncbi request reprint Pre-transplant minimal residual disease in children with acute lymphoblastic leukemia
    Parinda A Mehta
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Pediatr Blood Cancer 48:1-2. 2007
  8. ncbi request reprint Chemotherapy for myeloid malignancy in children with Fanconi anemia
    Parinda A Mehta
    Fanconi Anemia Comprehensive Care Center, Cincinnati Children s Hospital Medical Center CCHMC, Cincinnati, Ohio 45229, USA
    Pediatr Blood Cancer 48:668-72. 2007
  9. ncbi request reprint XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report
    Parinda A Mehta
    Cincinnati Children s Hospital and Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA
    Blood 107:39-45. 2006
  10. ncbi request reprint High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study
    Parinda Mehta
    Division of Hematology Oncology and PPRU, Cincinnati Children s Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio 45229, USA
    Biol Blood Marrow Transplant 12:235-40. 2006

Detail Information

Publications16

  1. ncbi request reprint Pharmacogenetics of acute lymphoblastic leukemia
    Parinda A Mehta
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Curr Opin Hematol 11:434-8. 2004
    ..This review discusses literature reports in this area and describes some of the challenges facing the field as it moves forward...
  2. doi request reprint Numerical chromosomal changes and risk of development of myelodysplastic syndrome--acute myeloid leukemia in patients with Fanconi anemia
    Parinda A Mehta
    Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Cancer Genet Cytogenet 203:180-6. 2010
    ....
  3. doi request reprint Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study
    Parinda A Mehta
    Division of Bone Marrow Transplantation Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Biol Blood Marrow Transplant 16:1458-62. 2010
    ..These data suggest that alternate day micafungin dosing, as described here, may provide an attractive alternative for antifungal prophylaxis in HSCT patients and merits further evaluation...
  4. pmc FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report
    Parinda A Mehta
    Division of Hematology Oncology, Cincinnati Children s Hospital and Medical Center, Cincinnati, Ohio 45229, USA
    Clin Cancer Res 14:7896-9. 2008
    ..We hypothesized that FAS genotype by altering susceptibility to apoptosis might affect outcome of childhood AML therapy...
  5. ncbi request reprint Allogeneic transplantation for childhood ALL
    P A Mehta
    Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Bone Marrow Transplant 41:133-9. 2008
    ..This review focuses on the appropriate use of transplantation for children with ALL and optimization of transplant procedures to improve survival and reduce late consequences of therapy...
  6. pmc Interleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia
    Parinda A Mehta
    Division of Haematology Oncology, Cincinnati Children s Hospital and Medical Center, Cincinnati, OH 45229, USA
    Br J Haematol 137:152-7. 2007
    ..We did not observe an association with IL-1alpha genotype in donor and/or recipient and transplant-outcome. These data suggest that the outcome of unrelated donor transplant for CML is not influenced by IL-1alpha genotype...
  7. ncbi request reprint Pre-transplant minimal residual disease in children with acute lymphoblastic leukemia
    Parinda A Mehta
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Pediatr Blood Cancer 48:1-2. 2007
  8. ncbi request reprint Chemotherapy for myeloid malignancy in children with Fanconi anemia
    Parinda A Mehta
    Fanconi Anemia Comprehensive Care Center, Cincinnati Children s Hospital Medical Center CCHMC, Cincinnati, Ohio 45229, USA
    Pediatr Blood Cancer 48:668-72. 2007
    ..In this report we describe the toxicity of a chemotherapy approach for patients with FA and myeloid malignancy to achieve cytoreduction prior to SCT...
  9. ncbi request reprint XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report
    Parinda A Mehta
    Cincinnati Children s Hospital and Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA
    Blood 107:39-45. 2006
    ..These data, representing the only data in pediatric AML, suggest that XPD genotype does not affect the etiology or outcome of childhood AML...
  10. ncbi request reprint High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study
    Parinda Mehta
    Division of Hematology Oncology and PPRU, Cincinnati Children s Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio 45229, USA
    Biol Blood Marrow Transplant 12:235-40. 2006
    ..Our data show measurable amphotericin B plasma concentrations 7 days after high-dose infusion of AmBisome. This suggests that once-weekly dosing, as described in this study, may provide useful protection against fungal infections...
  11. doi request reprint Pediatric acute lymphoblastic leukemia: is there still a role for transplant?
    Stella M Davies
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45230, USA
    Hematology Am Soc Hematol Educ Program 2010:363-7. 2010
    ..However, a rigorous approach must be taken in determining whether transplant does improve outcome whenever this strategy is applied...
  12. doi request reprint Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Blood 116:5824-31. 2010
    ..0001). We conclude that RIC significantly improves the outcome of patients with HLH undergoing allogeneic HCT...
  13. doi request reprint The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients
    Pooja Khandelwal
    Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital, Cincinnati, OH, USA
    Pediatr Transplant 18:94-102. 2014
    ..We conclude that alemtuzumab is effective for SR-aGVHD in pediatric patients with a tolerable spectrum of complications...
  14. pmc The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters
    Wei Du
    Divisions of Experimental Hematology and Cancer Biology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA
    Blood 119:4142-51. 2012
    ..In addition, oxidative stress-induced FANCD2 ubiquitination is required for the formation of a FA-BRG1-promoter complex. Taken together, these data identify a role for the FA pathway in cellular antioxidant defense...
  15. doi request reprint Bone marrow transplantation for inherited bone marrow failure syndromes
    Parinda Mehta
    Cincinnati Children s Hospital Medical Center and the University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Pediatr Clin North Am 57:147-70. 2010
    ..The rarity of these diseases coupled with the far more likely incremental improvements that will result from ongoing research will require prospective international clinical trials to improve the outcome for these children...
  16. pmc Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia
    Deepika Bhatla
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Br J Haematol 144:388-94. 2009
    ..59 +/- 12% AA and 55 +/- 14% AC; P = 0.40). These data indicate that children with a low activity CDA genotype are at increased risk of TRM with ara-C based therapy for AML...